ArticleFrontiers in oncology2026
Tumor apparent diffusion coefficient as a predictive marker for PD-1 inhibitor outcome in advanced cervical cancer: a retrospective study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate whether pre-treatment apparent diffusion coefficient (ADC) values from diffusion-weighted imaging (DWI) predict clinical outcomes in patients with advanced or locally advanced cervical cancer undergoing Programmed Death-1 (PD-1) inhibitor therapy. Despite the growing use of immunotherapy, reliable and non-invasive imaging biomarkers to predict treatment response in cervical cancer are lacking. Methods: This retrospective study analyzed 167 cervical cancer patients treated with PD-1 inhibitors at Wuhan Union Hospital between 01/05/2020 and 31/12/2023. The whole tumor ADC (wADC) and substantial tumor ADC (sADC; excluding necrotic, cystic, and vascular regions) were measured on the largest tumor slice. Optimal cut-off values for ADC and inflammatory markers were determined using X-tile software based on overall survival (OS). Progression-free survival (PFS) and OS were analyzed using Kaplan-Meier curves and Cox regression models. Results: Lower sADC was associated with significantly worse PFS (hazard ratio [HR] = 1.81; 95% confidence interval [CI]: 1.18-2.80; Conclusion: The substantial tumor ADC (excluding necrotic, cystic, and vascular regions) was associated with prognosis in cervical cancer patients receiving PD-1 inhibitor therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.